Latest News

Athenex Joins With Chinese Partner on Skin-Cancer Drug; to Receive $14.5 Million

Athenex (ATNX) said Thursday it has entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharmaceutical to develop and commercialize its drug KX2-391 for the treatment of actinic keratosis and oncology indications in China. Athenex said it will receive an upfront payment of $14.5 million, possible milestone payments of up to $15 million, and initial royalty payments of […]

US Stock Futures Sink After Apple’s Q1 Revenue Warning

US stock futures dropped sharply on Thursday after Apple (AAPL) slashed its fiscal Q1 revenue outlook, blaming a slowing Chinese economy. Oil prices nudged higher, buoyed by a reported drop in December crude exports from Saudi Arabia, with global benchmark Brent crude up 0.97%, and US crude West Texas Intermediate up 0.21% recently. At 8:15 am ET, the national employment […]

Sesen Bio Posts ‘Clinically Meaningful’ Data In Phase 3 Vicinium Trial; Shares Rise Nearly 3%

Sesen Bio Inc. (SESN) shares rose 2.7% during Thursday’s pre-market session after the biotech firm posted positive preliminary efficacy data from its ongoing phase 3 trial of Vicinium to treat patients with high-grade non-muscle invasive bladder cancer. Data from the Vista trial showed “clinically meaningful” complete response rates and the treatment was shown to be generally well-tolerated, the company said. […]